Search For "dcgi"
DCGI instructs pharma giants manufacturing remdesivir to upload details of
Updated : 5 years, 8 months ago IST
New Delhi [India], July 9 (ANI): Witnessing the incidence of black marketing and overcharging of the remdesivir injection above MRP, the Drugs Controller General of India (DCGI) has directed all three pharma giants--Cipla, Hetero, and Mylan to upload the details of anti-viral Remedsivir drug
Read More
Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per via
Updated : 5 years, 8 months ago IST
Bengaluru (Karnataka) [India], July 7 (ANI): Global pharmaceutical major Mylan has got approval for its remdesivir from the Drug Controller General of India (DCGI) and will launch a generic version of Gilead Sciences' COVID-19 anti-viral in the country at Rs 4,800 for 100 mg/vial.
Read More
DCGI permits human clinical trials for COVID-19 vaccine of Zydus Cadila
Updated : 5 years, 8 months ago IST
New Delhi [India], July 3 (ANI): The Drug Controller General of India (DCGI) on Thursday granted permission to pharma giant Zydus Cadila to conduct phase I and phase II human clinical trials for COVID -19 vaccine, a top government official told ANI.
Read More
DCGI gives nod to Mylan labs to manufacture remdesivir for 'restricted eme
Updated : 5 years, 8 months ago IST
New Delhi [India], July 2 (ANI): The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients, a senior government official said on Thursday.
Read More
DCGI gives nod to Bharat Biotech to conduct phase I & II Human clinica
Updated : 5 years, 8 months ago IST
New Delhi [India], June 30 (ANI): The Drug Controller General of India (DCGI) has granted permission to Bharat Biotech International Limited (BBIL) to conduct Phase I and II Human clinical trials to develop an indigenous vaccine for COVID-19 -- in the name COVAXIN.
Read More
Bharat Biotech announces India's first COVID-19 vaccine candidate 'COVAXIN
Updated : 5 years, 8 months ago IST
Hyderabad (Telangana) [India], June 30 (ANI): Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). Read More
Domestic pharma giants-- Cipla, Hetero got DCGI's nod to manufacture, sell
Updated : 5 years, 8 months ago IST
New Delhi [India], June 21 (ANI): In a significant development, India's top drug regulator has given nod to two domestic pharmaceutical companies--Cipla and Hetero for marketing authorization of anti-viral drug Remdesivir only for "restricted emergency use" on COVID-19 patients with moderate
Read More
Anti-viral drug favipiravir gets DGCI nod for 'restricted emergency use' i
Updated : 5 years, 8 months ago IST
New Delhi [India], June 19 (ANI): The Drug Controller General of India (DCGI) has granted permission to anti-viral drug favipiravir for "restricted emergency use" in mild to moderate cases of COVID-19, a senior government official confirmed to ANI.
Read More
Dr Reddy's Labs in licensing pact with Gilead Sciences for Remdesivir
Updated : 5 years, 9 months ago IST
Hyderabad (Telangana) [India], June 13 (ANI): Dr Reddy's Laboratories said on Saturday it has entered into a non-exclusive licensing agreement with Gilead Sciences Inc that will grant Dr Reddy's the right to register, manufacture and sell Gilead's investigational drug Remdesivir, a potent
Read More
Sun Pharma initiates phase two clinical trial on AQCH as potential treatme
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 5 (ANI): Sun Pharmaceutical Industries has started phase two clinical trial on AQCH, a phytopharmaceutical (plant-derived) drug for the treatment of COVID-19.
Read More
COVID-19: Pharma giants seek DCGI's approval to manufacture, sell Remdesiv
Updated : 5 years, 9 months ago IST
New Delhi [India], June 4 (ANI): Two domestic pharmaceutical firms--Mylan and Jubilant Life Sciences have approached the country's top drug regulator--Drug Controller General of India (DCGI) to seek its approval to manufacture and sell anti-viral drug 'Remdesivir' in India to combat COVID-19
Read More
Sun Pharma gets DCGI approval for clinical trial with Nafamostat in Covid-
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India], May 29 (ANI): Sun Pharmaceutical Industries said on Friday it has received approval from the Drugs Controller General of India (DCGI) to initiate clinical trial with Nafamostat Mesilate in Covid-19 patients.
Read More